Sintx Technologies (SINT) Q3 2026 earnings review
Sintx Technologies sales jump tenfold, but Q4 outlook drops
Sintx Technologies, a maker of ceramic medical implants and industrial parts, beat its own revenue target as aerospace shipments began. Third-quarter sales reached $2.19 million, more than double the $1.0 million middle of its plan, while operating losses fell in half to $1.64 million. Passing $2 million in product sales also allowed chief executive Eric Olson to call investor warrants after the quarter closed, bringing in $2 million in fresh cash.
| Revenue | $2.19M up from $0.21M a year ago; beat $0.9–1.1M plan |
|---|---|
| Gross margin | 62% 45% a year ago |
| Operating loss | $1.64M -51% from $3.36M a year ago |
| Q4 revenue outlook | Unchanged $1.0–1.3M (47% below Q3 at the middle) |
⚖️ Verdict: 🟢 Bullish
The story got better because the Utah factory proved it can fill commercial aerospace orders at a 62% gross margin while restoring its Nasdaq listing cushion. One caution: the company kept its fourth-quarter revenue plan at $1.0 million to $1.3 million, which by our math points to a 47% sales drop from the third quarter, and total shares outstanding have nearly doubled since December.
The question now is whether industrial ceramics can fund the company until its orthopedic implants generate meaningful sales. Either repeat aerospace orders keep factory revenue near $2 million a quarter, or sales drop back toward $1 million and force another round of share dilution. Fourth-quarter revenue and 2027 order bookings will tell.
🐂 Bull Case
Aerospace Orders More Than Doubled the Revenue Plan
Sintx Technologies makes silicon nitride ceramics, a tough material used in medical implants and aerospace parts. Chief executive Eric Olson said the third quarter showed the company can "turn industrial customer orders into revenue at scale through our U.S. manufacturing operations". In June, the Utah manufacturer booked more than $3.2 million in contract manufacturing orders. Shipments against those contracts began this quarter, with industrial parts for aerospace units of Fortune 500 corporations making up most of the sales.
- Total revenue: $2.19 million, up more than tenfold from $208,000 a year ago
- Previous third-quarter outlook: $0.9 million to $1.1 million
- Product revenue: $2.09 million, up from $150,000 a year ago
- Grant and contract revenue: $100,000, up from $58,000 a year ago
The shipments pushed total sales 119% above the middle of the company's own forecast, by our math, and roughly 380% above the second quarter. What to watch: new industrial purchase orders announced before year-end. Because the June order book was $3.2 million and Sintx just shipped roughly $2 million of products, the factory needs fresh contracts to stay busy in 2027.
Factory Volume Lifted Gross Margin by 17 Points
Running a ceramic plant with few orders leaves fixed factory costs unabsorbed. Sintx said third-quarter gross margin jumped to 62.2% from 44.7% a year ago on "improved pricing, higher manufacturing volumes, and increased production efficiencies". The cost of making the products dropped from 55.3% of revenue to 37.8%, a 17.5 percentage point improvement by our math. At the same time, management cut research and development spending by 57% from a year ago, to $548,000.
Higher gross profit and lower research spending cut the operating loss in half, to $1.64 million from $3.36 million a year ago. What to watch: fourth-quarter gross margin when sales step down toward the $1.15 million target. Holding gross margin above 50% on lower volume would show that pricing and plant efficiency gains are durable.
Warrant Call Added $2 Million and Kept Listing
Passing $2.0 million in quarterly product revenue unlocked a financing clause for the ceramics maker. Because product sales reached $2.09 million, Sintx gained the right to call roughly 1.88 million Class B warrants, which are contracts allowing holders to buy shares at $2.14 each or let them "automatically expire". After the quarter closed, investors exercised 941,423 warrants, or half the total by our math, giving Sintx $2.0 million in gross cash proceeds.
During the third quarter, the company also regained compliance with Nasdaq's $2.5 million minimum stockholders' equity rule, ending September with $3.39 million in equity. What to watch: year-end cash and stockholders' equity in the annual report. With fourth-quarter losses likely to consume most of the $3.39 million equity cushion, the $2.0 million post-quarter capital injection is what keeps the company above Nasdaq's listing floor.
🐻 Bear Case
Fourth-Quarter Plan Points to a 47% Sales Drop
A single quarter of contract shipments does not establish a steady run rate. In its October preliminary release, Sintx reiterated the fourth-quarter revenue forecast from its prior call, which puts fourth-quarter sales between $1.0 million and $1.3 million. At the $1.15 million middle of that range, revenue will fall 47.5% from the third quarter's $2.19 million by our math.
Even if the company hits the $1.3 million top of its fourth-quarter plan, three-month sales would drop by $890,000. That means third-quarter revenue included a batch of shipments from the $3.2 million June order book that will not repeat at the same pace next quarter. Because overhead costs were $3.0 million in the third quarter, a step-down in revenue will widen operating losses again unless management cuts expenses further.
What to watch: fourth-quarter product revenue and any 2027 sales outlook on the next earnings release. A drop back near $1.15 million without new order announcements would confirm that the third quarter was a one-off backlog clearing rather than a new baseline.
Industrial Parts Carry the Medical Device Pivot
"Our industrial business is providing an important commercial foundation as we pursue what we believe are even greater long-term opportunities in healthcare," chief executive Eric Olson said. Over the past year, Sintx sold or shut down non-core units to focus on medical devices, completing the initial limited release of its SiNAPTIC Foot & Ankle Osteotomy Wedge System, an implant for bone reconstruction surgery.
Yet the quarter's numbers moved the opposite way. Aerospace parts for Fortune 500 subsidiaries generated the majority of third-quarter sales, and the company did not disclose a dollar figure for SiNAPTIC or any other medical device. Meanwhile, Sintx cut research and development spending by 57% from a year ago to $548,000, while sales and marketing spend was just $140,000. A company spending $140,000 a quarter on marketing is not yet running a broad medical device launch.
What to watch: separate revenue disclosure for medical devices versus industrial ceramics in the full quarterly filing. Continued silence on medical revenue dollars would show that orthopedic implants remain too small to break out.
Share Count Nearly Doubled in Nine Months
Because Sintx loses money each quarter, it funds operations by selling new shares and warrants. Weighted average diluted shares rose 125% from a year ago, to 6.67 million from 2.96 million. Common shares outstanding on the balance sheet rose from 3.97 million at the end of 2025 to 6.89 million on September 30.
Adding the 941,423 Class B warrants exercised after the quarter ended takes total shares outstanding to 7.83 million by our math, up 97% in just over nine months. That means an investor who owned 1% of the company on December 31 now owns about half a percent. Because the company still lost $1.60 million even in a record revenue quarter, dilution will continue until gross profit covers the $3.0 million of quarterly operating expenses.
What to watch: usage of the at-the-market share sales facility in the fourth quarter. Issuing more shares right after collecting $2.0 million from warrants would signal that cash burn remains high.
👓 Other Themes
Preclinical Textile Studies Start for Wound Care
Sintx started large-animal studies testing medical textiles treated with silicon nitride, including surgical sutures and wound dressings. The trials test whether the ceramic coating kills bacteria, prevents tissue from sticking to dressings, and speeds up healing. Management expects the animal studies to finish in the first quarter of 2027, providing early data before any human clinical trials or commercial licensing.
💲 Other KPIs
Stockpiles of raw materials and ceramic parts more than doubled from the end of 2025. Total inventories rose 145% from $1.04 million at year-end (combining current and long-term inventory) to $2.56 million on September 30. Building inventory tied up $1.51 million in working capital as the plant prepared for aerospace and orthopedic orders.
Cash on hand fell by more than half over the first nine months of 2026, dropping 52% from $4.14 million at the end of December to $2.01 million on September 30. That drop occurred despite raising $5.0 million in the second quarter. Exercising the Class B warrants after September 30 added another $2.0 million in gross cash.
Corporate overhead grew while research spending shrank. Third-quarter general and administrative costs rose 7.1% from a year ago to $2.25 million, exceeding the entire quarter's $2.19 million revenue. Over the first nine months of 2026, overhead costs jumped 46.9% from a year ago to $7.10 million, eating up most of the company's financing proceeds.
🔮 Guidance
Unchanged. In the October preliminary release, the ceramics maker kept the fourth-quarter sales forecast from its second-quarter call, which sits at $1.0 million to $1.3 million. By our math, the $1.15 million middle of that range leaves fourth-quarter revenue 47.5% below the third quarter's $2.19 million, as the initial wave of June industrial shipments moderates.
❓ Key Questions
How much third-quarter revenue came from medical implants?
Sintx completed the initial rollout of its SiNAPTIC foot and ankle implant, but said aerospace parts drove the majority of third-quarter sales. Investors need the exact dollar split between medical devices and industrial ceramics to judge the healthcare pivot.
Why did management leave the fourth-quarter sales plan unchanged?
Third-quarter revenue beat the top of the company's forecast by $1.09 million, yet Sintx kept its fourth-quarter plan at $1.0 million to $1.3 million. Did customers pull fourth-quarter aerospace deliveries forward into September, or is the $3.2 million June order book taking longer to ship?
What drove the 47% jump in nine-month overhead costs?
General and administrative expenses rose from $4.84 million in the first nine months of 2025 to $7.10 million in 2026, even as research spending was cut in half. Management has not explained why corporate overhead is running above $2.2 million a quarter.
What is inside the $2.56 million inventory balance?
Total inventories rose by $1.51 million over the first nine months of 2026, while the fourth-quarter revenue plan calls for just $1.15 million in sales. How much of that stockpile is finished SiNAPTIC medical implants versus raw ceramic powder for aerospace contracts?